Pancreatic Cancer Research

ResearcherTongji UniversityNo recent work listed

Yong Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7812-0932; OpenAlex author ID A5014451809. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
26
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers

Papers 12

  1. Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model. Last author DOI 10.1093/g3journal/jkab296↗
  2. FOXM1-induced miR-552 expression contributes to pancreatic cancer progression by targeting multiple tumor suppressor genes. Last author DOI 10.7150/ijbs.56733↗
  3. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Co-author DOI 10.1038/s41388-019-1051-8↗
  4. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Co-author DOI 10.1158/1541-7786.mcr-18-0910↗
  5. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-1064↗
  6. Overexpression and biological function of MEF2D in human pancreatic cancer. Co-author PMID 29218083↗
  7. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Co-author DOI 10.1158/1078-0432.ccr-14-2437↗
  8. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.5772↗
  9. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator sys… Co-author DOI 10.1158/1078-0432.ccr-13-2311↗
  10. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Co-author DOI 10.1158/1078-0432.ccr-13-2407↗
  11. A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0186↗
  12. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Co-author DOI 10.1158/0008-5472.can-10-2016↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 8 shared papers, 2014–2020 · strength 0.52
  2. Ming Quan · 5 shared papers, 2015–2021 · strength 0.50
  3. Keping Xie · 8 shared papers, 2011–2020 · strength 0.44
  4. Dacheng Xie · 6 shared papers, 2014–2020 · strength 0.38
  5. Daoyan Wei · 5 shared papers, 2011–2017 · strength 0.23
  6. Zhiqin Chen · 1 shared paper, 2021 · strength 0.17
  7. Xiao Wang · 1 shared paper, 2021 · strength 0.16
  8. Sushovan Guha · 1 shared paper, 2020 · strength 0.12
  9. Liang Wang · 2 shared papers, 2015–2017 · strength 0.12
  10. Feng Jiao · 1 shared paper, 2019 · strength 0.10
  11. Haiyan Yang · 1 shared paper, 2019 · strength 0.10
  12. Liwei Wang · 1 shared paper, 2019 · strength 0.10
  13. Min Shi · 2 shared papers, 2014 · strength 0.09
  14. Zhiwang Song · 1 shared paper, 2017 · strength 0.08
  15. Chunyan Dong · 1 shared paper, 2017 · strength 0.08
  16. Qingyong Ma · 1 shared paper, 2017 · strength 0.07
  17. Kun Guo · 1 shared paper, 2017 · strength 0.07
  18. Chen Huang · 1 shared paper, 2014 · strength 0.05
  19. Qi Li · 1 shared paper, 2014 · strength 0.05
  20. Zhiwei Li · 1 shared paper, 2015 · strength 0.05
  21. Yanqiao Zhang · 1 shared paper, 2015 · strength 0.05
  22. Jiawei Du · 1 shared paper, 2014 · strength 0.04
  23. Shaojiang Zheng · 1 shared paper, 2014 · strength 0.04
  24. Jun Zhang Zhang · 1 shared paper, 2014 · strength 0.04
  25. Xiangyu Kong · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.